This company has tried to get funding for the trial of their "multi billion product" for three years now, and has failed. They owe money to a long list of toxic funders, and this is after converting enough debt into shares to run the O/S from 43M to over 1.6B.
They have to do something with the share structure as you've said. With 1.6B+ O/S and an A/S of 2B, there's not nearly enough room to accommodate this "plan." NASDAQ is a pipe dream, they won't nearly qualify and still won't have the capital to do the FDA trial.